Literature DB >> 22293763

The influence of ACPA status and characteristics on the course of RA.

Annemiek Willemze1, Leendert A Trouw, René E M Toes, Tom W J Huizinga.   

Abstract

Rheumatoid arthritis (RA) is one of the most common autoimmune diseases, and affects 0.5-1% of the population. Although it poses a considerable health problem, relatively little remains known about the disease pathogenesis and etiology. In the past decade, anti-citrullinated protein antibodies (ACPA) have emerged as suspects in the development and/or progression of RA. Citrullinated proteins--containing the amino acid citrulline, generated post-translationally from arginine--are found in the joints of patients with RA, but are not specific for the disease. This situation contrasts with the presence of ACPA, which are mostly found in individuals with RA. Intriguingly, ACPA can also be found in individuals before symptom onset. In these instances the ACPA response seems to be in its infancy, recognizing only a few citrullinated antigens and not using the full isotype repertoire. These characteristics of the ACPA response mature before clinical disease precipitates. Evidence is emerging that ACPA status can further characterize the heterogeneous RA phenotype, not only with respect to outcome, but perhaps also with respect to intervention. This Review summarizes the evolution of the ACPA response and its putative role in disease pathogenesis, as well as its relationship with clinical phenotype and diagnostic potential.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22293763     DOI: 10.1038/nrrheum.2011.204

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  105 in total

1.  2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Authors:  Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovsky; Frederick Wolfe; Gillian Hawker
Journal:  Ann Rheum Dis       Date:  2010-09       Impact factor: 19.103

2.  On the occurrence of a factor in human serum activating the specific agglutintion of sheep blood corpuscles. 1939.

Authors:  Erik Waaler
Journal:  APMIS       Date:  2007-05       Impact factor: 3.205

3.  Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles.

Authors:  S P Linn-Rasker; A H M van der Helm-van Mil; F A van Gaalen; M Kloppenburg; R R P de Vries; S le Cessie; F C Breedveld; R E M Toes; T W J Huizinga
Journal:  Ann Rheum Dis       Date:  2005-07-13       Impact factor: 19.103

4.  Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis.

Authors:  Lotte A van de Stadt; Margret H M T de Koning; Rob J van de Stadt; Gertjan Wolbink; Ben A C Dijkmans; Dörte Hamann; Dirkjan van Schaardenburg
Journal:  Arthritis Rheum       Date:  2011-11

5.  Absence of avidity maturation of autoantibodies to the protein tyrosine phosphatase-like IA-2 molecule and glutamic acid decarboxylase (GAD65) during progression to type 1 diabetes.

Authors:  Annette Westerlund; Matti Ankelo; Jorma Ilonen; Mikael Knip; Olli Simell; Ari E Hinkkanen
Journal:  J Autoimmun       Date:  2005-03       Impact factor: 7.094

6.  The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis.

Authors:  E J Kroot; B A de Jong; M A van Leeuwen; H Swinkels; F H van den Hoogen; M van't Hof; L B van de Putte; M H van Rijswijk; W J van Venrooij; P L van Riel
Journal:  Arthritis Rheum       Date:  2000-08

7.  Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies.

Authors:  G A Schellekens; B A de Jong; F H van den Hoogen; L B van de Putte; W J van Venrooij
Journal:  J Clin Invest       Date:  1998-01-01       Impact factor: 14.808

8.  Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis.

Authors:  Kristine A Kuhn; Liudmila Kulik; Beren Tomooka; Kristin J Braschler; William P Arend; William H Robinson; V Michael Holers
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

9.  Cutting edge: germinal centers formed in the absence of B cell-activating factor belonging to the TNF family exhibit impaired maturation and function.

Authors:  Kalpit A Vora; Li Chun Wang; Sambasiva P Rao; Zhong-Ying Liu; Gerard R Majeau; Anne H Cutler; Paula S Hochman; Martin L Scott; Susan L Kalled
Journal:  J Immunol       Date:  2003-07-15       Impact factor: 5.422

10.  The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis.

Authors:  Louise M A Jansen; Dirkjan van Schaardenburg; Irene van der Horst-Bruinsma; Rob J van der Stadt; Margret H M T de Koning; Ben A C Dijkmans
Journal:  J Rheumatol       Date:  2003-08       Impact factor: 4.666

View more
  71 in total

Review 1.  Genetic markers as therapeutic target in rheumatoid arthritis: A game changer in clinical therapy?

Authors:  A M Mohamed Thoufic Ali; S Vino
Journal:  Rheumatol Int       Date:  2016-09-16       Impact factor: 2.631

Review 2.  Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review.

Authors:  Emilio Martin-Mola; Alejandro Balsa; Rosario García-Vicuna; Juan Gómez-Reino; Miguel Angel González-Gay; Raimon Sanmartí; Estíbaliz Loza
Journal:  Rheumatol Int       Date:  2016-06-06       Impact factor: 2.631

3.  Rheumatoid arthritis: Seronegative and seropositive RA: alike but different?

Authors:  Sofia Ajeganova; Tom W J Huizinga
Journal:  Nat Rev Rheumatol       Date:  2014-11-18       Impact factor: 20.543

Review 4.  Beyond citrullination: other post-translational protein modifications in rheumatoid arthritis.

Authors:  Leendert A Trouw; Theo Rispens; Rene E M Toes
Journal:  Nat Rev Rheumatol       Date:  2017-03-09       Impact factor: 20.543

5.  Changes in anti-citrullinated protein antibody isotype levels in relation to disease activity and response to treatment in early rheumatoid arthritis.

Authors:  A Kastbom; K Roos Ljungberg; M Ziegelasch; J Wetterö; T Skogh; K Martinsson
Journal:  Clin Exp Immunol       Date:  2018-10-14       Impact factor: 4.330

6.  Rheumatoid arthritis: Autoantibody testing to predict response to therapy in RA.

Authors:  Leendert A Trouw; Rene E M Toes
Journal:  Nat Rev Rheumatol       Date:  2016-09-15       Impact factor: 20.543

Review 7.  Autoimmunity to citrullinated proteins and the initiation of rheumatoid arthritis.

Authors:  V Michael Holers
Journal:  Curr Opin Immunol       Date:  2013-11-08       Impact factor: 7.486

8.  Label-free detection of immune complexes with myeloid cells.

Authors:  Z Szittner; A E H Bentlage; P Rovero; P Migliorini; V Lóránd; J Prechl; G Vidarsson
Journal:  Clin Exp Immunol       Date:  2016-05-12       Impact factor: 4.330

Review 9.  Pre-rheumatoid arthritis: predisposition and transition to clinical synovitis.

Authors:  William P Arend; Gary S Firestein
Journal:  Nat Rev Rheumatol       Date:  2012-08-21       Impact factor: 20.543

10.  Genetic variants in the region of the C1q genes are associated with rheumatoid arthritis.

Authors:  L A Trouw; N Daha; F A S Kurreeman; S Böhringer; G N Goulielmos; H J Westra; A Zhernakova; L Franke; E A Stahl; E W N Levarht; G Stoeken-Rijsbergen; W Verduijn; A Roos; Y Li; J J Houwing-Duistermaat; T W J Huizinga; R E M Toes
Journal:  Clin Exp Immunol       Date:  2013-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.